Skip to main content

INVESTORS & MEDIA

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent News
04/06/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2020-- Seres Therapeutics, Inc. , (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke , M.D., FCP, as Executive Vice President and Chief Medical Officer. Dr. von Moltke joins Seres with an extensive career that includes senior leadership
03/30/20
 – Topline ECOSPOR III Phase 3 study data readout timing as planned for mid-2020 – – Potential for ECOSPOR III to be a single pivotal study supporting product registration with FDA – – Company assessing the impact of COVID-19 on SER-287, SER-401 and SER-301 clinical development programs –
03/23/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 23, 2020-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Paul Biondi , Executive Partner at Flagship Pioneering, to its Board of Directors. Noubar Afeyan , Ph.D., a co-founder of Seres and Chief Executive Officer of Flagship
There are currently no events to display.
Stock Quote
:
 
 

E-mail Alerts

Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Request Information

Obtain investor relations information by contacting us.

More

Back to top